These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 12149599

  • 1. Acarbose improves indirectly both insulin resistance and secretion in obese type 2 diabetic patients.
    Delgado H, Lehmann T, Bobbioni-Harsch E, Ybarra J, Golay A.
    Diabetes Metab; 2002 Jun; 28(3):195-200. PubMed ID: 12149599
    [Abstract] [Full Text] [Related]

  • 2. Effect of acarbose on insulin sensitivity in elderly patients with diabetes.
    Meneilly GS, Ryan EA, Radziuk J, Lau DC, Yale JF, Morais J, Chiasson JL, Rabasa-Lhoret R, Maheux P, Tessier D, Wolever T, Josse RG, Elahi D.
    Diabetes Care; 2000 Aug; 23(8):1162-7. PubMed ID: 10937515
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with Type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study.
    Halimi S, Le Berre MA, Grangé V.
    Diabetes Res Clin Pract; 2000 Sep; 50(1):49-56. PubMed ID: 10936668
    [Abstract] [Full Text] [Related]

  • 4. Effect of acarbose on additional insulin therapy in type 2 diabetic patients with late failure of sulphonylurea therapy.
    Standl E, Baumgartl HJ, Füchtenbusch M, Stemplinger J.
    Diabetes Obes Metab; 1999 Jul; 1(4):215-20. PubMed ID: 11228756
    [Abstract] [Full Text] [Related]

  • 5. Long-term effect of acarbose on glycaemic control in non-insulin-dependent diabetes mellitus: a placebo-controlled double-blind study.
    Hotta N, Kakuta H, Sano T, Matsumae H, Yamada H, Kitazawa S, Sakamoto N.
    Diabet Med; 1993 Mar; 10(2):134-8. PubMed ID: 8458189
    [Abstract] [Full Text] [Related]

  • 6. Addition of benfluorex to biguanide improves glycemic control in obese non-insulin-dependent diabetes: a double-blind study versus placebo.
    Roger P, Auclair J, Drain P.
    J Diabetes Complications; 1999 Mar; 13(2):62-7. PubMed ID: 10432168
    [Abstract] [Full Text] [Related]

  • 7. Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes.
    Juhl CB, Pørksen N, Pincus SM, Hansen AP, Veldhuis JD, Schmitz O.
    Diabetes; 2001 Aug; 50(8):1778-84. PubMed ID: 11473038
    [Abstract] [Full Text] [Related]

  • 8. Acarbose treatment does not change the habitual diet of patients with Type 2 diabetes mellitus. The Finnish Acargbos Study Group.
    Lindström J, Tuomilehto J, Spengler M.
    Diabet Med; 2000 Jan; 17(1):20-5. PubMed ID: 10691155
    [Abstract] [Full Text] [Related]

  • 9. Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients.
    Fischer S, Patzak A, Rietzsch H, Schwanebeck U, Köhler C, Wildbrett J, Fuecker K, Temelkova-Kurktschiev T, Hanefeld M.
    Diabetes Obes Metab; 2003 Jan; 5(1):38-44. PubMed ID: 12542723
    [Abstract] [Full Text] [Related]

  • 10. The investigation of the efficacy of insulin glargine on glycemic control when combined with either repaglinide or acarbose in obese Type 2 diabetic patients.
    Duran C, Tuncel E, Ersoy C, Ercan I, Selimoglu H, Kiyici S, Guclu M, Erturk E, Imamoglu S.
    J Endocrinol Invest; 2009 Jan; 32(1):69-73. PubMed ID: 19337019
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and tolerability of acarbose in Asian patients with type 2 diabetes inadequately controlled with diet and sulfonylureas.
    Lin BJ, Wu HP, Huang HS, Juang JH, Sison A, bin Abdul Kadir DK, Cho CG, Sridama W, Writing Group for the Asian Study of Acarbose with Sulfonylureas.
    J Diabetes Complications; 2003 Jan; 17(4):179-85. PubMed ID: 12810240
    [Abstract] [Full Text] [Related]

  • 12. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.
    Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, Ryan EA, Tan MH, Wolever TM.
    Ann Intern Med; 1994 Dec 15; 121(12):928-35. PubMed ID: 7734015
    [Abstract] [Full Text] [Related]

  • 13. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study.
    Coniff RF, Shapiro JA, Robbins D, Kleinfield R, Seaton TB, Beisswenger P, McGill JB.
    Diabetes Care; 1995 Jun 15; 18(6):817-24. PubMed ID: 7555508
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes.
    Kelley DE, Bidot P, Freedman Z, Haag B, Podlecki D, Rendell M, Schimel D, Weiss S, Taylor T, Krol A, Magner J.
    Diabetes Care; 1998 Dec 15; 21(12):2056-61. PubMed ID: 9839094
    [Abstract] [Full Text] [Related]

  • 20. Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with Type 2 diabetes.
    Hanefeld M, Haffner SM, Menschikowski M, Koehler C, Temelkova-Kurktschiev T, Wildbrett J, Fischer S.
    Diabetes Res Clin Pract; 2002 Mar 15; 55(3):221-7. PubMed ID: 11850098
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.